+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Arterial Thrombosis - Pipeline Review, H1 2019

  • ID: 4772673
  • Drug Pipelines
  • May 2019
  • Region: Global
  • 57 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Bristol-Myers Squibb Co
  • GLSynthesis Inc
  • Thromboserin Ltd
  • XBiotech Inc
  • MORE
Arterial Thrombosis - Pipeline Review, H1 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Arterial Thrombosis - Pipeline Review, H1 2019, provides an overview of the Arterial Thrombosis (Cardiovascular) pipeline landscape.

Arterial thrombosis is a blood clot that develops in an artery. Symptoms include lack of pulse, pain or spasms in the muscles, pale skin and coldness. Depending on where the clot forms, arterial thrombosis can cause several serious conditions, including stroke, heart attack and peripheral arterial disease (PAD). Predisposing factors include smoking, obesity, diabetes, hypertension and high cholesterol level. Treatment includes thrombolytic agents and surgery.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Arterial Thrombosis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Arterial Thrombosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Arterial Thrombosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Arterial Thrombosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Arterial Thrombosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Arterial Thrombosis (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Arterial Thrombosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Arterial Thrombosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Arterial Thrombosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Arterial Thrombosis (Cardiovascular)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Arterial Thrombosis (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Arterial Thrombosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Bristol-Myers Squibb Co
  • GLSynthesis Inc
  • Thromboserin Ltd
  • XBiotech Inc
  • MORE
Introduction

Report Coverage

Arterial Thrombosis - Overview

Arterial Thrombosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Arterial Thrombosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Arterial Thrombosis - Companies Involved in Therapeutics Development

Astellas Pharma Inc

Bristol-Myers Squibb Co

GLSynthesis Inc

Jiangsu Hengrui Medicine Co Ltd

Thromboserin Ltd

XBiotech Inc

Arterial Thrombosis - Drug Profiles

ASP-6537 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bermekimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-654457 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GLS-409 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OA-150 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PZ-128 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-007867 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-2285 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Integrin alpha 2 beta 1 for Arterial Thrombosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PAI1 for Immunology, Respiratory and Cardiovascular Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Factor XIa for Arterial Thrombosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

THL-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Arterial Thrombosis - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Arterial Thrombosis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Arterial Thrombosis - Pipeline by Astellas Pharma Inc, H1 2019

Arterial Thrombosis - Pipeline by Bristol-Myers Squibb Co, H1 2019

Arterial Thrombosis - Pipeline by GLSynthesis Inc, H1 2019

Arterial Thrombosis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2019

Arterial Thrombosis - Pipeline by Thromboserin Ltd, H1 2019

Arterial Thrombosis - Pipeline by XBiotech Inc, H1 2019

Arterial Thrombosis - Dormant Projects, H1 2019

Arterial Thrombosis - Dormant Projects, H1 2019 (Contd..1), H1 2019

List of Figures

Number of Products under Development for Arterial Thrombosis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Astellas Pharma Inc
  • Bristol-Myers Squibb Co
  • GLSynthesis Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Thromboserin Ltd
  • XBiotech Inc
Note: Product cover images may vary from those shown
Adroll
adroll